Withaferin A

Pharmacology & Research

Withaferin A is the best-known steroidal lactone (withanolide) of ashwagandha and one of the most-studied natural anticancer molecules. Before any claim, the defining caveat: withaferin A is present at only trace-to-low levels in oral ashwagandha root, the form used in virtually all human trials (KSM-66, Sensoril/Shoden). So ashwagandha’s clinical adaptogen, stress, sleep and testosterone benefits are not attributable to withaferin A — the herb’s tolerability and the molecule’s pharmacology are separate stories. The molecule itself is a reactive electrophile: its α,β-unsaturated steroidal lactone acts as a Michael acceptor that covalently modifies reactive cysteines on many proteins, which is why it hits a broad target list (proteasome, HSP90, vimentin, NF-κB) ^{1,2,3,4Reference 1Yang H et al. · 2007The tumour proteasome is a primary target for the natural anticancer compound withaferin A isolated from Indian winter cherryView study →Reference 2Yu Y et al. · 2010Withaferin A targets heat-shock protein 90 in pancreatic cancer cellsView study →Reference 3Bargagna-Mohan P et al. · 2007The tumour inhibitor and antiangiogenic agent withaferin A targets the intermediate-filament protein vimentinView study →Reference 4Ichikawa H et al. · 2006Withanolides potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis through suppression of NF-κB activation and NF-κB-regulated gene expressionView study →} and why it is cytotoxic rather than drug-like. Its entire efficacy literature is preclinical.

1. Anticancer

Withaferin A is one of the most-studied natural anticancer molecules, with convergent, verified targets: proteasome inhibition (the chymotrypsin-like 20S proteasome, in prostate cancer) ^{1Reference 1Yang H et al. · 2007The tumour proteasome is a primary target for the natural anticancer compound withaferin A isolated from Indian winter cherryView study →}, HSP90-client degradation (pancreatic cancer) ^{2Reference 2Yu Y et al. · 2010Withaferin A targets heat-shock protein 90 in pancreatic cancer cellsView study →}, covalent vimentin binding that blocks epithelial-mesenchymal transition and metastasis ^{3Reference 3Bargagna-Mohan P et al. · 2007The tumour inhibitor and antiangiogenic agent withaferin A targets the intermediate-filament protein vimentinView study →}, NF-κB pathway suppression ^{4Reference 4Ichikawa H et al. · 2006Withanolides potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis through suppression of NF-κB activation and NF-κB-regulated gene expressionView study →}, anti-angiogenesis ^{5Reference 5Mohan R et al. · 2004Withaferin A is a potent inhibitor of angiogenesisView study →}, and activity in B-cell lymphoma ^{6Reference 6McKenna MK et al. · 2015Anti-cancer activity of withaferin A in B-cell lymphomaView study →}.

Gap: essentially all evidence is cell-line and rodent xenograft — there is no human oncology trial of the isolated molecule, and the score reflects mechanistic depth, not clinical proof ^{7Reference 7Vyas AR · 2014Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactoneView study →}.

2. Anti-inflammatory / inflammasome

Withaferin A inhibits NLRP3-inflammasome activation and IL-1β release — in Helicobacter pylori-driven dendritic cells ^{8Reference 8Kim J et al. · 2015Withaferin A inhibits Helicobacter pylori-induced production of IL-1β in dendritic cells by regulating NF-κB and NLRP3 inflammasome activationView study →} and in a macrophage/fulminant-hepatitis model ^{9Reference 9Xia Y et al. · 2021Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3View study →} — and suppresses NF-κB-regulated inflammatory genes ^{4Reference 4Ichikawa H et al. · 2006Withanolides potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis through suppression of NF-κB activation and NF-κB-regulated gene expressionView study →}.

Gap: preclinical only, and mechanistically overlapping with the anticancer NF-κB story (the same pathway papers recur) ^{8,9Reference 8Kim J et al. · 2015Withaferin A inhibits Helicobacter pylori-induced production of IL-1β in dendritic cells by regulating NF-κB and NLRP3 inflammasome activationView study →Reference 9Xia Y et al. · 2021Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3View study →}.

3. Metabolic (leptin sensitiser)

In a widely-cited study, withaferin A reduced body weight ~20–25% in diet-induced obese mice, improved hepatic steatosis and insulin sensitivity, and worked only in leptin-signalling-intact animals — hence “leptin sensitiser” — while attenuating ER stress ^{10Reference 10Lee J et al. · 2016AnimalWithaferin A is a leptin sensitiser with strong antidiabetic properties in miceView study →}.

Gap: a single lab’s mouse model with no human data, and the weight effect may be partly confounded by the molecule’s general cytotoxicity/stress signalling ^{10Reference 10Lee J et al. · 2016AnimalWithaferin A is a leptin sensitiser with strong antidiabetic properties in miceView study →}.

4. Immunomodulatory

Some reports describe immunogenic cell death — but the most-cited such study used a root DMSO extract, not isolated withaferin A ^{11Reference 11Turrini E et al. · 2016Withania somnifera induces cytotoxic and cytostatic effects on human T-leukemia cellsView study →}, so it is weak support for the pure molecule.

Gap: the effect is biphasic and largely a byproduct of cytotoxicity; this is not a clean immunomodulator claim ^{11Reference 11Turrini E et al. · 2016Withania somnifera induces cytotoxic and cytostatic effects on human T-leukemia cellsView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
20S proteasome (chymotrypsin-like)	covalent inhibition → pro-apoptotic substrate accumulation	anticancer
HSP90 chaperone	disrupts HSP90–Cdc37, degrades client oncoproteins	anticancer (pancreatic etc.)
Vimentin (Cys328)	covalent Michael adduct → filament aggregation, blocks EMT	anti-metastatic, anti-angiogenic
NF-κB (IKK/p65)	suppresses activation and NF-κB-regulated genes	anticancer + anti-inflammatory
NLRP3 inflammasome	inhibits assembly → ↓ IL-1β	anti-inflammatory
Leptin signalling / ER stress	sensitises leptin response, reduces ER stress	metabolic

Unifying mechanism: withaferin A is a reactive electrophile whose unsaturated lactone acts as a Michael acceptor covalently modifying reactive cysteines — the promiscuity that explains both its broad target list and its cytotoxicity.

Pharmacokinetics

Load-bearing. Withaferin A is a reactive electrophile / covalent binder — its Michael-acceptor chemistry forms covalent adducts with protein cysteine thiols (vimentin Cys328, the proteasome, and others) ^{3,1Reference 3Bargagna-Mohan P et al. · 2007The tumour inhibitor and antiangiogenic agent withaferin A targets the intermediate-filament protein vimentinView study →Reference 1Yang H et al. · 2007The tumour proteasome is a primary target for the natural anticancer compound withaferin A isolated from Indian winter cherryView study →}, which is why it hits many targets and why it is cytotoxic rather than drug-like. Its pharmacokinetics are characterised only in animal models, with poor drug-likeness (high reactivity, low selectivity) and no validated human PK. And oral exposure from ashwagandha root is low — withaferin A is trace-to-low in whole-root products (leaf is richer), so the root-based standardised extracts used in human trials deliver minimal withaferin A, and systemic exposure to the molecule from typical supplementation is small.

Clinical trials

There is no published human efficacy trial of purified withaferin A for any indication. Human ashwagandha trials test root extracts low in withaferin A and cannot serve as evidence for the molecule — their stress, sleep, anxiety and testosterone results should not be attributed to withaferin A. The entire efficacy literature for withaferin A is preclinical.

Last checked: July 2026.

Toxicity & Safety

This page concerns isolated withaferin A, not whole ashwagandha root — and the two are very different. The molecule is intrinsically cytotoxic: it is investigated precisely because it kills cells (apoptosis, cell-cycle arrest, ROS generation, mitochondrial disruption), and its Michael-acceptor reactivity means non-selective covalent protein binding, i.e. off-target liability at higher exposure. It is not sold as a standalone supplement, and whole-root ashwagandha’s good tolerability does not transfer to the purified molecule. Its cytotoxic, antiproliferative and antiangiogenic activity also raises a plausible reproductive-toxicity concern. Interactions are theoretical, from mechanism rather than clinical data: additive effects with proteasome or HSP90 inhibitors or other cytotoxic chemotherapeutics, modulation of NF-κB/immune signalling alongside immunosuppressants, and possible additive glucose/leptin effects with antidiabetic agents ^{10Reference 10Lee J et al. · 2016AnimalWithaferin A is a leptin sensitiser with strong antidiabetic properties in miceView study →}. The moderate flag reflects an honest middle: the reactive cytotoxicity argues toward “high,” but real-world human exposure occurs almost entirely via low-withaferin-A root extracts, and there is no isolated-molecule human toxicity dataset to anchor a higher call.

Dosage

No human therapeutic dose exists and none is recommended. For context only, research doses are: in vitro, typically low-micromolar (~0.5–10 µM) for anticancer/anti-inflammatory effects; in mice, ~1.25–5 mg/kg/day intraperitoneally in the metabolic study ^{10Reference 10Lee J et al. · 2016AnimalWithaferin A is a leptin sensitiser with strong antidiabetic properties in miceView study →}, with oncology xenograft studies commonly ~2–8 mg/kg intraperitoneally. These are experimental parenteral animal doses in cytotoxicity research and are emphatically not a supplement or human-use recommendation.

References